Baird raised the firm’s price target on Agenus (AGEN) to $6 from $4 and keeps a Neutral rating on the shares. The firm updatedits model following the receipt of ts $91M upfront payment from its strategic collaboration with Zydus.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGEN:
- Strategic Collaboration Between Agenus and Zydus Lifesciences Boosts Financial Position and Product Development
- Agenus upgraded to Buy from Neutral at H.C. Wainwright
- Agenus selling U.S. manufacturing facilities to Zydus
- Agenus, Zydus enter $141M collaboration for BOT/BAL production orders
- Agenus presents new translational data at 2025 ASCO meeting